GraphRAG (Graph Retrieval-Augmented Generation)

Instead of retrieving isolated text chunks by vector similarity, GraphRAG queries a knowledge graph composed of semantic triples (subject-predicate-object). This allows the retriever to follow explicit, named relationships between entities, fetching a structured subgraph of interconnected facts rather than a flat list of documents. The retrieval is deterministic and relationship-aware, eliminating the noise of keyword or embedding drift.

GraphRAG excels at queries requiring the synthesis of multiple, non-adjacent facts. The system performs graph traversal to navigate paths between entities, such as connecting a patient's symptom to a drug's mechanism of action through intermediate genes and pathways. This multi-hop capability is powered by query languages like Cypher or SPARQL, which express complex pattern-matching logic that a simple vector search cannot replicate.

A key innovation in Microsoft's GraphRAG is the Leiden community detection algorithm. The system partitions the knowledge graph into hierarchical communities of closely related entities and generates natural language summaries for each. When a query is received, these summaries provide a high-level, thematic understanding of the entire dataset, allowing the LLM to answer broad, abstract questions that require synthesizing information across thousands of documents.

By anchoring retrieval in canonical entity nodes with unique identifiers, GraphRAG dramatically reduces hallucination. The system resolves ambiguous mentions through entity linking to a controlled vocabulary, ensuring that the context provided to the LLM is about the correct, specific real-world object. This is critical in domains like healthcare, where confusing a drug's brand name with its generic ingredient can have severe consequences.

Production GraphRAG systems often combine node embeddings (dense vectors) with graph traversal (sparse, symbolic logic). An initial vector search locates entry points into the knowledge graph, and then a graph traversal expands the context by following edges. This hybrid approach marries the fuzzy, semantic understanding of embeddings with the precise, logical rigor of a graph database, optimizing for both recall and precision.

The pipeline begins with an LLM extracting entities and relations from source documents to construct the graph. This process, known as relation extraction, identifies subject-predicate-object triples directly from text. The result is a dynamic, queryable property graph where nodes and edges hold attributes. This transforms a static corpus into a living, interconnected knowledge base that can be updated incrementally without full re-indexing.

GraphRAG enables pharmacovigilance teams to traverse complex networks of drugs, targets, pathways, and adverse events to identify causal signals.

• Traverses drug-protein-disease pathways to explain unexpected side effects
• Links patient demographics and comorbidities to adverse event clusters
• Grounds LLM-generated safety narratives in structured biomedical ontologies like MedDRA and RxNorm

Example: A GraphRAG system can connect a patient's medication list to a knowledge graph of metabolic pathways, identifying that Drug A inhibits the enzyme metabolizing Drug B, explaining a toxicity spike.

GraphRAG accelerates patient recruitment by reasoning over complex inclusion/exclusion criteria against a knowledge graph of patient histories.

• Models patient journeys as temporal graphs of diagnoses, procedures, and lab results
• Performs multi-hop reasoning to verify complex criteria like 'failed two prior lines of therapy'
• Links genomic variants to trial eligibility through SNOMED CT and Human Phenotype Ontology mappings

Example: A query for 'non-small cell lung cancer patients with EGFR exon 20 insertion mutations who progressed on platinum-based chemotherapy' is resolved by traversing diagnosis, genomic, and treatment edges in the graph.

GraphRAG enhances diagnostic decision support by grounding LLM reasoning in structured relationships between symptoms, diseases, and patient context.

• Traverses symptom-disease edges weighted by prevalence and co-occurrence
• Incorporates patient-specific factors like age, sex, and comorbidities as graph constraints
• Ranks candidate diagnoses using graph centrality and semantic proximity algorithms

Example: For a patient presenting with fatigue, weight loss, and hypercalcemia, the system traverses from symptoms to diseases, prioritizing conditions that explain all three findings while considering the patient's cancer history.

GraphRAG automates the assembly of clinical evidence for payer-provider authorization workflows by linking patient data to coverage policies and medical literature.

• Maps extracted clinical findings to policy criteria encoded as graph patterns
• Retrieves supporting evidence from guideline-to-recommendation edges
• Generates audit-ready justification narratives grounded in structured clinical logic

Example: For a biologic therapy request, the system verifies step therapy requirements by traversing the patient's medication history graph, confirming failure of first-line treatments before generating the approval summary.

GraphRAG identifies latent disease risks by analyzing patient comorbidity graphs against population-level disease progression networks.

• Constructs personalized disease graphs from longitudinal patient records
• Applies graph neural network embeddings to predict future diagnoses
• Grounds predictions in known pathophysiological pathways from biomedical knowledge graphs

Example: A patient with type 2 diabetes and hypertension triggers traversal of downstream complication nodes, surfacing elevated risk for chronic kidney disease and recommending preemptive nephrology referral.

GraphRAG supports clinical decision-making by reasoning over treatment protocol graphs that encode guideline-directed therapy sequences and their outcomes.

• Models National Comprehensive Cancer Network (NCCN) guidelines as directed treatment graphs
• Matches patient-specific biomarkers to therapy eligibility nodes
• Compares alternative pathways using outcome-weighted edge traversal

Example: For a breast cancer patient with HER2+ status, the system navigates the guideline graph to recommend first-line trastuzumab-based therapy, while flagging clinical trial nodes for patients with specific resistance mutations.